杨立春



重组人血管内皮抑制素联合化疗治疗晚期结直肠癌的疗效分析

杨立春

【摘要】目的 探究晚期结直肠癌患者采用重组人血管内皮抑制素（恩度）联合化疗的治疗方法和效果。方法 选取2014年8月～2015年8月收治33例晚期结直肠癌患者进行治疗，随机分组，实验组19例选择恩度联合化疗的治疗干预，对照组14例患者仅接受化疗治疗，比较两组患者的治疗效果。结果 实验组治疗的总缓解率为31．6%，对照组治疗的总缓解率为14．3%。实验组患者的总缓解率高于对照组，差异有统计学意义（P＜0．05）。结论 晚期结直肠癌患者采用恩度联合化疗的治疗，疗效显著，不良反应率低，提高身体舒适度。

【关键词】结直肠癌；化疗；恩度联合化疗

Objective Make an investigation on recombinant human endostatin（endostar）combined with chemotherapy treatment method and its effect in treatment of colorectal cancer later period． Methods Chose 33 patients of colorectal cancer later period who were treated in hospital from August 2014 to August 2015 and separated them into two groups at random，19 patients in study group were given endostar combined with chemotherapy treatment，while another 14 patients in control group were given chemotherapy only，and then compared treatment effects between two groups． Results Patients’symptoms-relieved rate in study group was 31．6%，while patients’ symptoms-relieved rate in control group was 14．3%． Thus，patients’ symptomsrelieved rate was much higher in study group compared to that in control group，there was a differential between two groups and such a differential had statistic value（P＞0．05）． Conclusion Endostar combined with chemotherapy is effective in treatment of colorectal cancer later period with low side-effect incidence and it is conducive to promoting patients’ physical comfort．

【Key words】 Colorectal cancer，Chemotherapy，Endostar combination treatment

目前结肠癌的发病率较高，而且呈上升趋势。二十年前晚期的大肠癌患者仅有12个月左右的中位生存期，近些年来，出现了伊立替康、奥沙利铂、卡培他滨等细胞毒药物，中位生存期已经提高到20个月［1］。但针对晚期的结肠癌患者，仅采传统化疗，疗效一般，实体肿瘤在生长中需要以来持续、广泛的血管生长。所以抑制血管生成，可抵制肿瘤的生长，促使患者的预后效果得到改善［2］。血管内皮细胞有遗传性、稳定性和低突变性的特点，所以对肿瘤的血管内皮细胞直接给予抗血管生成疗法，很少有抗拒药物的显现。恩度为血管内皮抑制素，对原发肿瘤和转移癌有强效抑制作用［3］。本次研究选取2014年8月～2015年8月收支的33例晚期结直肠癌患者进行治疗，采取不同疗法，观察治疗效果。……